(1) Background: The oncology field has drastically changed with the advent of precision
medicine, led by the discovery of druggable genes or immune targets assessed through next …

Cervical cancer still represents a major public health problem, being the fourth most
common cancer in incidence and mortality in women worldwide. These figures are …

Background Immune checkpoint inhibitors targeting PD-1 or CTLA-4 individually have
shown substantial clinical benefits in the treatment of malignancies. We aimed to assess the …

Background The GOG240 trial established bevacizumab with chemotherapy as standard
first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10 …

Background Cervical cancer is the fourth most cancer and the fourth leading cause of cancer-
related deaths in women worldwide. Current treatment for patients with advanced cervical …

Currently, for ovarian cancer, which has the highest mortality rate among all gynecological
cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by …

Purpose: Immune checkpoint inhibitors (ICI) have been a potential treatment option for
patients with cervical cancer in several clinical studies. We investigated the safety and …

Simple Summary Approaches beyond first-line chemotherapy to treat advanced cervical
cancer (CC) are currently limited. Immune checkpoint inhibitors (ICIs) are showing high …

Introduction Despite progress on prevention and treatment of cervical cancer, global
morbidity and mortality remain high. Immunotherapy, in conjunction with standard …

Abstract Purpose of Review This review aims to give an insight into the currently available
options for recurrent/metastatic (R/M) cervical cancer (CC), along with the main future …